^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Salivary Gland Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    Perjeta (pertuzumab) (HER2 dimerization inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

    Excerpt:
    ...Confirmed diagnosis of a malignancy harbouring HER2 amplification, or an appropriate activating mutation as defined by the MTB, using an analytically validated method....
    Trial ID:
    DETERMINE
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

    Excerpt:
    Thirty of 114 patients (26%; 95% CI, 19% to 35%) with HER2 amplification/overexpression had objective responses to treatment with trastuzumab plus pertuzumab (two CR, 28 PR). Objective responses were seen in nine primary tumor types: colorectal, bladder, biliary, salivary gland, NSCLC, pancreas, ovary, prostate, and skin (apocrine; Table 3).
    DOI:
    10.1200/JCO.2017.75.3780
    Trial ID:
    NCT02091141